Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

St. Mark's Episcopal Church is a parish of the Episcopal Church in Cocoa, Brevard County, Florida, in the Episcopal Diocese of Central Florida.

The decision comes in the wake of changes to Novartis' organisational structure, including the merger ... adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys Discover ...

Specifically, the GenAI and foundation model will be used to look at sequence, structure ... adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys Imagine a time when ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $210.00. Don't Miss ...

Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00. Don't Miss our Black Friday Offers: Luke Sergott has ...